Whitepaper
9 Oct 2019
DETECTION OF MYCOPLASMA IN BIOPHARMACEUTICALS VACCINES AND GENE CELL THERAPIES
PDF 125 kB
Content provided by our supplier
SGS
-
US
-
2015On CPHI since
Other Content from SGS (4)
-
News SGS joins with Biophytis to launch international trial of COVID-19 related respiratory failure treatment
The CRO will undertake this clinical trial at multiple sites worldwide, starting at the AZ Sint Maarten hospital in Mechelen, Belgium. -
Brochure Bioanalysis Testing Solutions
With over 30 years of experience and operating out of our GLP/GCP compliant laboratories. SGS has the expertise to both develop assays from scratch (including LC-MS/MS, immunoassays and cell-based assays) and to support large scale routine sample analyses, from regulatory pre-clinical (toxicology) to early and late clinical studies (Phase I to IV).
-
News OneVision: Creating a Global Standardized Laboratory Network for SGS Life Sciences
SGS launches OneVision, a global digitalization initiative to standardize record-keeping procedures across all Life Sciences’ testing laboratories.
-
News SGS Expands Extractables and Leachables Testing Capabilities at its Shanghai Facility
SGS has significantly increased its capabilities to undertake extractables and leachables (E&L) testing at its Shanghai, China, laboratory.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance